Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540760 | 0.98 | GHSR (0.49) | GHSRKISS1R | |
| SCHEMBL29884151 | 0.92 | NPY4R (0.47) | GHSR | |
| SCHEMBL30592734 | 0.92 | NPY4R (0.47) | GHSR | |
| SCHEMBL30081066 | 0.91 | NPY1R (0.49) | GHSR | |
| SCHEMBL29540123 | 0.91 | NPY1R (0.49) | GHSR | |
| SCHEMBL30592737 | 0.91 | NPY1R (0.49) | GHSR | |
| SCHEMBL6824254 | 0.90 | LNPEP (0.47) | — | |
| SCHEMBL6824252 | 0.90 | LNPEP (0.47) | — | |
| SCHEMBL4906337 | 0.88 | NPY1R (0.50) | GHSR | |
| SCHEMBL4906380 | 0.88 | NPY1R (0.50) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-12297502-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | CORNELL UNIVERSITY (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | CORNELL UNIVERSITY (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230033758-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-11534476-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11266709-B2 | Methods for the regulation of matrix metalloproteinase expression | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | HSPA9, OPA1, ARG2 | GHSR 3737/4885KISS1R 3601/4885 |
| US-11534476-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | GHSR 918/4885KISS1R 2379/4885 |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | NLN, OAT, HAGH | GHSR 3379/4885KISS1R 3690/4885 |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | MUSK, TNNC1, TNNI3 | GHSR 469/4885KISS1R 2814/4885 |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | ARG2, SERPINC1, ARG1 | GHSR 1450/4885KISS1R 764/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | GHSR 3931/4885KISS1R 3486/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | GHSR 4526/4885KISS1R 4494/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | GHSR 2407/4885KISS1R 3269/4885 |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | GHSR 1557/4885KISS1R 2510/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | GHSR 4658/4885KISS1R 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.